- Providers
- Conference
SABCS 2022
Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during the San Antonio Breast Cancer Symposium 2022.
Advancing The Standards Of Breast Cancer Care With Comprehensive Somatic Next-Generation Sequencing, Germline Testing, And AI-Driven Data
Learn more about our portfolio of comprehensive sequencing and how we are leveraging data to advance precision oncology.
If you missed the live presentation, the product theatre webinar recording can be found on our website following the SABCS meeting.
Featuring Calvin Chao, M.D., Senior Vice President of Medical Affairs, Tempus Cynthia Ma, M.D., PhD, Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center
DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a Chemotherapy-Free Maintenance Strategy in Platinum Treated Advanced Triple-Negative Breast Cancer (aTNBC)
Sarah Sammons; Duke Ezequiel Renzulli; Tempus
The mutational landscape of 1172 patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors
Recent studies suggest possible differences in outcomes among MBC patients treated with palbociclib, ribociclib, or abemaciclib, but whether differences have a genomic basis is unknown. Tempus’ multimodal real-world dataset analyzed 1172 HR+ HER2- MBC patients who received >6 months of CDK4/6i therapy, with focus on comparing genomic and immune biomarker landscapes from Tempus tissue and liquid biopsy testing following each specific CDK4/6i therapy.
Ami Shah; Northwestern Adam Brufsky; UPMC Calvin Chao; Tempus
Gene expression and mutation profiles in HER2-mutated metastatic breast cancer
In comparing the mutational landscapes and gene expressions of HER2-mutated MBC patients to HER2-amplified and HER2-wild type MBC patients, Tempus’ multimodal real-world dataset showed different co-occurring genomic alterations among the three groups, while increased HER2 mRNA expression was noted in both HER2-mut and HER2-amp MBC patients.
Cynthia Ma; Washington University Ron Bose; WUSTL Sherif El-Refai; Tempus
Molecular characterization of HER2-low patients identifies basal-enriched subset with poor clinical outcomes in real-world data
Tempus multimodal real-world data reveals that HER2-low breast cancers are comprised of distinct molecular subtypes. HER2-low patients were clustered according to our HER2 expression signature identifying three distinct molecular clusters. A distinct cluster of predominantly basal-like HER2-low patients had shorter real world PFS than other HER2-low patients (n=57). These data further reveal the utilization of RNA expression to fully characterize clinically relevant subpopulations.
Halla Nimeiri; Tempus Rotem Ben-Shachar; Tempus
Dual ctDNA and tissue sequencing improves detection of actionable variants in patients with breast cancer
Of breast cancer patients sequenced concurrently (samples collected ≤ 30 days apart) with liquid- and tissue-based NGS tests who had actionable genomic findings , 20% had unique findings identified in liquid alone that would have been missed by solid testing, while 29% had unique findings identified in solid tissue (n=93/473 and n=136/473, respectively).
Matthew MacKay; Tempus Rotem Ben-Shachar; Tempus
Genomic Landscape of ER+/HER2- metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
Tempus’ multimodal real-world dataset assessed the landscape of somatic alterations from both tissue and liquid biopsies in 1853 HR+ HER2- MBC patients who either received or did not receive prior CDK4/6i therapy, providing insights into potential mechanisms of resistance following such therapies. Patients with prior CDK4/6i therapy harbored significantly more ESR1 somatic alterations, demonstrated in both solid tissue and liquid biopsies.
M Rosario Chica-Parrado; UTSW Ariella Hanker; UTSW Carlos Arteaga; UTSW Liz Mauer; Tempus
Schedule a meeting with us
We'll be in touch shortly.